Abstract
Introduction Polysubstance use is the use of more than one non-prescribed licit or illicit substance at one time. This is a common phenomenon, but little is known about the severity and the various substances used by adults in Malaysia.
Objective To determine the pattern of polysubstance use and its associated factors among general adults in Malaysia.
Methodology This was a secondary data analysis from the National Health and Morbidity Survey (NHMS) 2019), a cross-sectional population survey with a two-stage stratified random sampling design. A total of 10,472 Malaysians aged 18 years and above participated in this survey. Polysubstance use was defined as concurrent use of more than one substance, either alcohol, tobacco, or drugs (opioid, marijuana, amphetamine/ methamphetamine or kratom). A latent class analysis (LCA) was used to identify the membership of polysubstance groups. The association of class membership with demographic profiles was examined using Multinomial Logistic Regression analysis.
Results Fit indices (AIC =16458.9, BIC = 16443.6) from LCA supported 3 classes solution: i) Combination of tobacco and alcohol (Tob+Alc) use (2.4%), ii) multi-drug use including kratom (0.3%) and iii) non/negligible user (97.3%). The multinomial model showed young adults (18-40 years) had a higher likelihood of being polysubstance users both for Tob+Alc class (OR=4.1) and multi-drug class (OR=3.9) compared to older age (≥60 years). Chinese (OR = 18.9), Indian (OR =23.3), Indigenous Sabah & Sarawak (OR =34.6) and others ethnicity (OR =8.9) showed higher odds of being Tob+Alc users than Malays. The greater odds of Tob+Alc. use for male (OR =35.5), working group (OR =1.5) and low education level group (OR=3.2).
Conclusion Our study highlights patterns and demographics related to the use of polysubstance among adults in Malaysia. These results would help formulate specific prevention programmes for these high risk groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
he author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia (NMRR-18-3085-44207)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
↵* shaki_iera{at}yahoo.com (WSRH)
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos